{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dyspepsia-proven-functional/prescribing-information/levofloxacin/","result":{"pageContext":{"chapter":{"id":"6075addb-8b4a-5e26-9d73-a9cd48dd70f3","slug":"levofloxacin","fullItemName":"Levofloxacin","depth":2,"htmlHeader":"<!-- begin field 475b1b1a-c943-41d5-98b9-a7470165693a --><h2>Levofloxacin</h2><!-- end field 475b1b1a-c943-41d5-98b9-a7470165693a -->","summary":"","htmlStringContent":"<!-- begin item 7f15a60a-9942-4c2c-aff9-a74701656ad7 --><!-- end item 7f15a60a-9942-4c2c-aff9-a74701656ad7 -->","topic":{"id":"5cc1cb73-764f-51c5-bc62-44f807111272","topicId":"36754870-050c-4543-8dfe-bee25a1d10bb","topicName":"Dyspepsia - proven functional","slug":"dyspepsia-proven-functional","lastRevised":"Last revised in October 2018","chapters":[{"id":"8b6fdb09-e6f3-5061-8539-ae2f57647698","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"63a6aa45-5022-5194-bebc-bd4481b831fe","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6cdc4376-525a-5e58-8be2-dd0831642d02","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"257ffcf8-d6ac-58d1-b852-f9bb7329f249","slug":"changes","fullItemName":"Changes"},{"id":"d05055eb-ebd0-5056-b860-1ea85daeb311","slug":"update","fullItemName":"Update"}]},{"id":"b6f4608e-164d-578d-8142-8b175799683f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bf8575af-2f9b-5729-a628-5efb1ed0411d","slug":"goals","fullItemName":"Goals"},{"id":"761ef9c0-39a0-5dd7-9216-2dc7963b0a6a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"694c1d21-0d63-5dc6-bb90-b5acdbeb64ab","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9244dd4a-0551-5975-b909-6d728dfadcdd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9029a91f-3843-5e59-8544-cb7adfa2c457","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"19b1713f-a518-57e7-a0c1-cdb48d0b4a0d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"e265526e-adb9-5805-aedd-2e2bc77bb54c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"93b80ba3-9d73-5fc5-8b0e-7a57de8d6107","slug":"definition","fullItemName":"Definition"},{"id":"8f596c75-9a83-5d33-8b9a-4d18a9e24e2e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0a9f461a-38b9-56d1-8511-e41e822e0e8a","slug":"complications","fullItemName":"Complications"},{"id":"e7524b44-b1cf-50d9-806d-bd52695ec307","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a156deba-ce54-58e0-8984-13e20203cd70","fullItemName":"Management","slug":"management","subChapters":[{"id":"ff03390b-be65-558d-83cf-6808e0b84339","slug":"management-of-functional-dyspepsia","fullItemName":"Scenario: Management of functional dyspepsia"}]},{"id":"40a9d515-33a2-5915-b7db-28a3edf79724","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c3d76d92-046e-5ac3-84fa-c59eff3cd774","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors"},{"id":"8ad244d5-29e6-5577-8efb-eae73fd2faad","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"},{"id":"29d86046-683d-5047-a344-9b0961e8916a","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"891aafa8-13c0-5175-b0ac-580bd4cbe1b8","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"c11610d4-e4be-5dbb-baf5-5414f7bea599","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"a8c93904-08fc-57a4-b238-068ab96b5615","slug":"tetracycline","fullItemName":"Tetracycline"},{"id":"6075addb-8b4a-5e26-9d73-a9cd48dd70f3","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"348b1111-2664-52e1-9fd6-2d26abd69bcb","slug":"bismuth","fullItemName":"Bismuth"}]},{"id":"2d629b23-aa42-5503-980b-2c202de4c387","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4be75458-608e-5c04-9441-7001ced7fc6d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6ad0185f-1607-5a33-9e94-892b09578c17","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6489fce3-cac9-583f-a217-70ba5562de71","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e29927f4-a004-5126-a503-f1045ce72a28","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ca579371-2f3e-59ad-887e-7215f885a62a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"de65b79c-b356-54be-a611-9a871e60c85e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"43271e4f-f094-520d-bd20-f6582fc6ba97","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"40a9d515-33a2-5915-b7db-28a3edf79724","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"a79f0768-4ac5-5b97-89a8-346ec333cfe4","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 30607fdb-b398-4927-b593-a74a015e4aca --><h3>Contraindications and cautions</h3><!-- end field 30607fdb-b398-4927-b593-a74a015e4aca -->","summary":"","htmlStringContent":"<!-- begin item ea998723-3dca-47c5-8b44-a74a015e48dd --><!-- begin field ab32d89c-9483-4e2d-9671-a74a015e4aca --><ul><li><strong>Do not prescribe levofloxacin to people with:</strong><ul><li>A history of quinolone hypersensitivity.</li><li>A history of tendon disorders related to quinolone use — tendon damage (including rupture) has been reported rarely in people taking quinolones. If suspected, stop levofloxacin immediately.</li></ul></li><li><strong>Prescribe levofloxacin with caution to people with:</strong><ul><li>A history of epilepsy or a condition that predisposes to seizures — quinolones may induce seizures.</li><li>Conditions which may prolong the QT interval (for example, electrolyte disturbances, acute myocardial infarction, heart failure with reduced ejection fraction, bradycardia, a history of symptomatic arrhythmias, and concomitant use of other drugs known to prolong the QT interval).</li><li>An increased risk of tendon damage (for example, people taking concomitant corticosteroids) — tendon damage (including rupture) has been reported rarely in people taking quinolones.</li><li>Chronic kidney disease (CKD) stages 4 and 5 — if the estimated glomerular filtration rate (eGFR) is 20–50 mL/minute/1.73 m<sup>2</sup>, prescribe the usual initial dose then half the normal levofloxacin dose.</li><li>Glucose 6-phosphate dehydrogenase (G6PD) deficiency — possible increased risk of acute haemolytic anaemia when taking quinolones.</li><li>A history of psychiatric illness.</li><li>Myasthenia gravis — there is a risk of exacerbation of symptoms.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">BNF 72, 2016</a>]</p><!-- end field ab32d89c-9483-4e2d-9671-a74a015e4aca --><!-- end item ea998723-3dca-47c5-8b44-a74a015e48dd -->","subChapters":[]},{"id":"b7fc49c3-34c0-5857-8a2b-34bb7aecada6","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 49d09a57-cf7f-44b6-9f1a-a74a015f2b89 --><h3>Adverse effects</h3><!-- end field 49d09a57-cf7f-44b6-9f1a-a74a015f2b89 -->","summary":"","htmlStringContent":"<!-- begin item 6503d5c3-42db-47be-b311-a74a015f288a --><!-- begin field 9bd1d473-6696-43d9-b1cd-a74a015f2b89 --><ul><li>Adverse effects of levofloxacin include nausea, vomiting, diarrhoea, headache, and dizziness.<ul><li>Consider pseudomembranous colitis if a person develops severe diarrhoea during or after treatment with levofloxacin. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li>Less frequent adverse effects include:<ul><li>Dyspepsia, abdominal pain, anorexia, sleep disturbances, confusion, anxiety, depression, hallucinations, seizures and tremor. Quinolones may lower the seizure threshold and may trigger seizures. Levofloxacin is contraindicated in patients with a history of epilepsy and, as with other quinolones, should be used with extreme caution in patients predisposed to seizures, or concomitant treatment with active substances that lower the cerebral seizure threshold, such as theophylline. In case of convulsive seizures, treatment with levofloxacin should be discontinued.</li><li>Blood disorders (including eosinophilia, leucopenia, and thrombocytopenia), arthralgia, tendinitis, tendon rupture, myalgia, rash (very rarely Stevens-Johnson syndrome and toxic epidermal necrolysis), disturbances in vision and taste, and photosensitivity.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">BNF 72, 2016</a>]</p><!-- end field 9bd1d473-6696-43d9-b1cd-a74a015f2b89 --><!-- end item 6503d5c3-42db-47be-b311-a74a015f288a -->","subChapters":[]},{"id":"b20312c0-f536-572a-9a0a-ac4b37ace4a9","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 8bc754b7-55a4-48a8-8a99-a74a015f8f4c --><h3>Drug interactions</h3><!-- end field 8bc754b7-55a4-48a8-8a99-a74a015f8f4c -->","summary":"","htmlStringContent":"<!-- begin item 2e15ced3-1844-4d7a-ac16-a74a015f8eb6 --><!-- begin field 5b289180-5b30-48e2-b199-a74a015f8f4c --><p><strong>Possible drug interactions with levofloxacin include:</strong></p><ul><li><strong>Amiodarone </strong>— increased risk of ventricular arrhythmias when levofloxacin given with amiodarone. Avoid concomitant use.</li><li><strong>Antacids </strong>— absorption of levofloxacin reduced by antacids. Give at least 2 hours before or 4 hours after levofloxacin.</li><li><strong>Anticoagulants </strong>— levofloxacin possibly increases the anticoagulant effect of drugs such as warfarin. Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li><li><strong>Iron salts and zinc </strong>— absorption of levofloxacin reduced by oral iron salts. Give at least 2 hours apart.</li><li><strong>Aminophylline and theophylline </strong>— possible increased risk of convulsions when levofloxacin given with aminophylline and theophylline.</li><li><strong>Ciclosporin </strong>— increased risk of nephrotoxicity when levofloxacin given with ciclosporin.</li><li><strong>Nonsteroidal anti-inflammatory drugs (NSAIDs) </strong>— possible increased risk of convulsions when levofloxacin given with NSAIDs.</li><li><strong>Zolmitriptan </strong>— levofloxacin possibly inhibits the metabolism of zolmitriptan. Reduce the dose of zolmitriptan.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">BNF 72, 2016</a>]</p><!-- end field 5b289180-5b30-48e2-b199-a74a015f8f4c --><!-- end item 2e15ced3-1844-4d7a-ac16-a74a015f8eb6 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}